CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.
Home/Biomarker

BRAF non-V600 — resistance to vemurafenib

Gene: BRAF · Type: mutation

Indications: Melanoma

Linked CIViC Profile: BRAF MUTATION

Evidence Level Distribution

Level B: 10Level D: 2
LevelTypeDirectionSignificanceDiseaseDrugsRating
DPredictiveSupportsSensitivity/ResponseCancerTrametinib4
BPrognosticSupportsPoor OutcomeColorectal Cancer4
BPrognosticSupportsPoor OutcomeColorectal Cancer4
BPredictiveDoes Not SupportSensitivity/ResponseColorectal CancerPanitumumab,Cetuximab3
BPredictiveSupportsResistanceColorectal CancerCetuximab,Chemotherapy3
BPrognosticSupportsPoor OutcomeColorectal Cancer3
BPredictiveSupportsResistanceColorectal CancerOxaliplatin3
BPredictiveSupportsResistanceColorectal CancerIrinotecan3
BPredictiveSupportsResistanceColorectal CancerBevacizumab3
BPredictiveSupportsResistanceColorectal CancerCetuximab3
BPrognosticSupportsPoor OutcomeColorectal Cancer3
DPredictiveSupportsResistanceColorectal CancerCetuximab2